Building on our success with UDENYCA® (pegfilgrastim-cbqv), we are now expanding our mission to immuno-oncology with Junshi Biosciences’ novel
Toripalimab is an investigational new drug currently being evaluated by the FDA for commercial distribution in the United States.
“Alan was truly a titan of the biotech industry, without peer in his discipline, and this is such tremendous loss on so many levels for so many people. His contributions and impact on the industry through its genesis and evolution are difficult to overstate. I am honored to have had him as a decades-long personal friend, inspiring mentor, and the most trusted of advisors. Alan tenaciously advocated for Coherus from the start and through all subsequent phases of the Company’s evolution. His influence on our company is profound, and we are grateful for his wise counsel. On behalf of the entire Coherus team and our Board of Directors, I offer our deep and heartfelt condolences to the Mendelson family.”—Denny Lanfear, CEO of Coherus.